title: Interactions of doxycycline with chemotherapeutic agents in human breast adenocarcinoma MDA-MB-231 cells.
abstract: Commonly used chemotherapeutic agents for breast cancer treatment include cisplatin, doxorubicin, and paclitaxel. Unfortunately, these effective antiproliferative agents are limited by their toxicities. Previously, we have shown that doxycycline can substantially reduce tumor burden in an animal model of breast cancer bone metastasis. The purpose of this study was to examine the effect of doxycycline in combination with chemotherapy. Human breast adenocarcinoma MDA-MB-231 cells were treated in vitro with each drug individually and in combination with doxycycline. Cell survival was determined using the clonogenic survival assay. Doxycycline in combination with doxorubicin or paclitaxel yielded therapeutic antagonism at all effect levels. Combinatory treatment with cisplatin, however, yielded a biphasic interaction, at low combinatorial doses, the effect was quantified as nearly additive, whereas higher doxycycline-cisplatin doses yielding greater than 50% cell inhibition resulted in synergistic effects. Cell cycle profiles were determined and showed that treatment with doxycycline, cisplatin, and doxorubicin resulted in G1-phase, S-phase, and G2/M-phase arrests, respectively. Upon addition of doxycycline to doxorubicin, the G2/M-arrest characteristic of doxorubicin-only treatment was abrogated, which may account for the observed antagonism. Cells treated with doxycycline and cisplatin showed a further increase in S-phase arrest, also observed with cisplatin alone, which may be responsible for the additive and synergistic effects on cell survival. We clearly show that doxycycline in combination with paclitaxel or doxorubicin treatment resulted in antagonism; however, combining doxycycline with cisplatin led to synergistic interactions at higher effect levels. The increased potency of cisplatin may warrant dose reduction and thus decrease toxicity in vivo.
authors.affiliation: Juravinski Cancer Centre, McMaster University, Hamilton, Ontario, Canada.
authors.forename: Faryar
authors.initials: F
authors.lastname: Foroodi
authors.forename: Wilhelmina C
authors.initials: WC
authors.lastname: Duivenvoorden
authors.forename: Gurmit
authors.initials: G
authors.lastname: Singh
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy*; D000970:Antineoplastic Agents / Q000494:pharmacology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D001943:Breast Neoplasms / Q000188:drug therapy*; D002453:Cell Cycle / Q000187:drug effects; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D002945:Cisplatin / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000494:pharmacology; D004318:Doxycycline / Q000494:pharmacology*; D004347:Drug Interactions; D004357:Drug Synergism; D005260:Female; D006801:Humans; D020128:Inhibitory Concentration 50; D017239:Paclitaxel / Q000494:pharmacology
chemical_list: D000970:Antineoplastic Agents; D004317:Doxorubicin; D004318:Doxycycline; D017239:Paclitaxel; D002945:Cisplatin